Federico De Leonardis

Dr. Federico De Leonardis

Fondazione Policlinico Tor Vergata, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
FLFederico De Leonardis
Federico De Leonardis
GCGaia Colalillo
Gaia Colalillo
EAEnrico Finazzi Agro
Enrico Finazzi Agro
RMRoberto Miano
Roberto Miano
AFAndrea Fuschi
Andrea Fuschi
AAAnastasios D. Asimakopoulos
Anastasios D. Asimakopoulos
Erectile dysfunction (ED) is a condition with multifactorial pathogenesis, quite common among men, especially those above 60 years old. A vascular etiology is the most common cause. The interaction between chronic inflammation, androgens, and cardiovascular risk factors determines macroscopically invisible alterations such as endothelial dysfunction and subsequent atherosclerosis and flow-limiting stenosis that affects both penile and coronary arteries. Thus, ED and cardiovascular disease (CVD) should be considered two different manifestations of the same systemic disorder, with a shared aetiological factor being endothelial dysfunction. Moreover, the penile arteries have a smaller size compared with coronary arteries; thus, for the same level of arteriopathy, a more significant blood flow reduction will occur in erectile tissue compared with coronary circulation. As a result, ED often precedes CVD by 2–5 years, and its diagnosis offers a time window for cardiovascular risk mitigation. Growing evidence suggests, in fact, that patients presenting with ED should be investigated for CVD even if they have no symptoms. Early detection could facilitate prompt intervention and a reduction in long-term complications. In this review, we provide an overview of the pathogenetic mechanisms behind arteriogenic ED and CVD, focusing on the role of endothelial dysfunction as the common denominator of the two disorders. Developed algorithms that may help identify those patients complaining of ED who should undergo detailed cardiologic assessment and receive intensive treatment for risk factors are also analyzed.

10 February 2025 in Complications
Verified
Journal Article
Open access
PDF file
RMRebeca Escobar Monroy
Rebeca Escobar Monroy
SPSilvia Proietti
Silvia Proietti
FLFederico De Leonardis
Federico De Leonardis
SGStefano Gisone
Stefano Gisone
RSRiccardo Scalia
Riccardo Scalia
GGGuido Giusti
Guido Giusti
Purpose: Percutaneous nephrolithotomy (PCNL) is the gold-standard treatment for large renal calculi. Despite its efficacy, complications can occur. This narrative review aims to classify, manage, and prevent PCNL complications, emphasizing risk factors and strategies to optimize outcomes. Findings: PCNL is a safe and highly effective procedure for the management of renal stones. Risk factors include patient comorbidities, stone complexity, prolonged surgical time, and improper access. Proactive measures, such as accurate imaging, antibiotic prophylaxis, and careful surgical techniques, reduce complication rates. Although certain complications may affect surgical outcomes, most are effectively managed through conservative or minimally invasive approaches. Proficiency in the technique is essential for reducing the risk of complications. Conclusions: Understanding the classification, risk factors, and management of PCNL complications is essential for optimizing patient outcomes. Comprehensive preoperative planning, meticulous surgical technique, and tailored postoperative care are critical for minimizing risks and improving procedural safety.

15 July 2025 in European Urology Focus
Verified
Journal Article
Closed access
CHCristian Axel Hernandez-Gaytan
Cristian Axel Hernandez-Gaytan
SPSilvia Proietti
Silvia Proietti
FLFederico De Leonardis
Federico De Leonardis
LMLuca Mongelli
Luca Mongelli
FGFranco Gaboardi
Franco Gaboardi
GGGuido Giusti
Guido Giusti

26 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SPSilvia Proietti
Silvia Proietti
CHCristian Axel Hernández-Gaytán
Cristian Axel Hernández-Gaytán
FLFederico De Leonardis
Federico De Leonardis
SGStefano Gisone
Stefano Gisone
RSRiccardo Scalia
Riccardo Scalia
GGGuido Giusti
Guido Giusti
Upper tract urothelial carcinoma (UTUC) accounts for approximately 5–10% of urothelial malignancies and represents a clinically challenging disease due to its frequent presentation at advanced stages and its association with significant morbidity. Radical nephroureterectomy (RNU) with bladder cuff excision remains the standard treatment for high-risk disease; however, this approach inevitably results in loss of renal function and may significantly affect eligibility for cisplatin-based chemotherapy. In patients with imperative indications for renal preservation—including a solitary kidney, bilateral disease, or advanced chronic kidney disease—Kidney-Sparing Surgery (KSS) represents an essential therapeutic strategy. Technological advances in flexible ureteroscopy, improved visualization systems, and laser energy sources have significantly expanded the feasibility of conservative management. Ureteroscopic tumor ablation has become the cornerstone of KSS, allowing local disease control while preserving renal function. Although recurrence rates remain relatively high, repeated endoscopic treatment combined with strict surveillance protocols can achieve acceptable oncological outcomes in carefully selected patients. This narrative review summarizes the current evidence regarding conservative management of UTUC in imperative clinical situations, with particular emphasis on patient selection, endoscopic treatment modalities, laser technologies, economic implications, patient counselling, and follow-up strategies.

10 April 2026 in Journal of Intensive Care Medicine
Verified
Journal Article
Closed access
IPIvonne Portaccio
Ivonne Portaccio
OGOrazio Genovese
Orazio Genovese
FLFederico De Leonardis
Federico De Leonardis
IVIlaria Vitali
Ilaria Vitali
EPEnzo Picconi
Enzo Picconi
MPMarco Piastra
Marco Piastra
Background: Ventilator-associated pneumonia (VAP) remains the second most common nosocomial infection in pediatric intensive care units, yet evidence-based prevention strategies specific to children remain limited. Objective: To evaluate the efficacy of a multimodal VAP prevention bundle incorporating 0.12% chlorhexidine oral care in reducing VAP incidence among mechanically ventilated pediatric patients. Methods: Controlled before-after study in the Gemelli PICU (January 2016-May 2019) including 162 patients aged 2 years, saline for younger children), head-of-bed elevation 30°-40°, biweekly microbiological surveillance, and daily weaning assessment. Primary outcome was VAP incidence using CDC/NHSN criteria. Results: Bundle implementation was associated with a 69.5% reduction in VAP incidence (20% to 6.1%, P = .01), decreasing from 3.3 to 1.0 VAP/100 ventilator-days. The number needed to treat was 7.2 patients. Protocol implementation reduced VAP risk (adjusted OR 0.23; 95% CI 0.07-0.81; P = .022). VAP-associated mortality was lower in the intervention group (0% vs 3.8% in controls). Duration of mechanical ventilation remained the strongest risk factor (OR 1.18 per day; 95% CI 1.08-1.29; P < .001). Pseudomonas aeruginosa was identified in 57.1% of VAP cases, with polymicrobial infections in 52.4%. All isolates remained antibiotic-susceptible. Conclusions: Structured implementation of an evidence-based VAP bundle may contribute to significant reductions in preventable VAP in pediatric intensive care. While findings are promising, the modest sample size necessitates cautious interpretation and validation through larger multicenter studies.